Ardent Health heads into its May 6 earnings call with the headline numbers already on the table — a Q1 beat that punched through modest expectations.
The company posted Q1 EPS of $0.28, well clear of the $0.20 consensus estimate. Revenue came in at $1.601 billion against an estimate of $1.582 billion. Full-year 2026 guidance was affirmed: EPS of $0.90–$1.27 versus the $1.13 street estimate, and sales of $6.40–$6.70 billion against a $6.567 billion forecast. The beat has done work — the stock is up 17% over the past month and 4.3% on the week, reaching $10.13 at Tuesday's close.
The short-lending picture reflects little conviction from bears. Short interest is a modest 2.1% of free float — not a level that signals aggressive positioning. The monthly build of roughly 31% in shares short is worth noting, but borrow conditions are extremely loose. Availability is well-supplied, cost to borrow is just 0.52%, and the short score of 57 has actually eased over the past week. Options traders are similarly relaxed: the put/call ratio of 0.15 is marginally below its 20-day average of 0.16, with a z-score near zero. There is no meaningful defensive hedging in the run-up to the call.
The analyst backdrop remains constructive despite a consistent drumbeat of target cuts over recent months. RBC Capital and Leerink Partners both trimmed targets in March — following the prior earnings print that sent the stock down 7.7% in a day — but each maintained Outperform ratings. JPMorgan has held Neutral with an $11 target, nearly in line with current levels. The mean target across the Street is $12.44, implying roughly 23% upside from current prices. Bulls point to Ardent's position in high-demand urban markets and a new revenue management platform as longer-term margin catalysts. Bears are focused on payor denials, higher professional fees, and limited capital flexibility for expansion given the company's rural-market exposure and concentrated ownership structure — Equity Group Investments controls 54% of shares.
That ownership structure is noteworthy context. With the float constrained by two anchor holders controlling over 75% of shares combined, the tradeable base is small — which helps explain the low short interest in absolute terms. CEO Martin Bonick and CFO Alfred Lumsdaine both made token share sales in late March and early April at prices around $8.56–$8.67, well below today's level, carrying minimal significance given their size. The May 6 call will test whether the Q1 beat and reaffirmed guidance are enough to shift the remaining analyst skepticism — particularly on whether improving payor dynamics and the revenue management transition can translate into sustainable margin recovery rather than a one-quarter bounce.
See the live data behind this article on ORTEX.
Open ARDT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
